2018 SLAS Americas Sample Management Symposium

Today's tough targets require new screening technologies to identify novel chemical matter, a blend of functional and structural approaches to interrogate targets in orthogonal assays, and a diverse collection of chemical matter. Traditionally, small molecules of ~ 500 MW and large molecules eg antibodies of ~ 150000 MW have been the focus of drug discovery and development. The need for middle molecules spanning this MW range and with appropriate drug properties is a challenge and opportunity. In this talk, screening strategies, technologies and follow-up assays will be discussed as they are applied to examples of tough targets.